Skip Navigation
Print This Page
Share this page: More

Developing Novel Diagnostic Strategies to Define Pathologic Features in MS and TM Patients

An important research endeavor in many disease entities has been the development of better and novel diagnostic strategies in the form of non-invasive imaging, biomarkers and neuronal markers of injury. These markers are critical as objective measures of outcome in designing clinical trials.

Development of novel imaging strategies:

To better define the pathology and subtypes of transverse myelitis (TM) and multiple sclerosis (MS), we must develop novel imaging strategies for patients. Although conventional MRI approaches effectively define abnormal regions within the nervous system, they do not precisely define what that abnormality is. Emerging technologies allow a more precise understanding of pathology in the nervous system and can identify appropriate therapeutic interventions in the phase during which those interventions are likely to be helpful.

Proteomics to develop biomarkers:

The past decade has seen much research focused on gene expression arrays that have identified several novel transcripts in MS brain tissue. Proteomics is a relatively newer field that holds significant promise for identifying individual proteins or patterns of proteins that are involved in MS.

Johns Hopkins Medicine has a large proteomics facility that includes several mass spectroscopy units, gas chromatography, HPLC, and a dedicated bioinformatics unit.

This facility has been further coupled with laser capture microscopy and thus has the ability to work with complex biological material to identify unique proteins, peptides, lipids, or carbohydrate moieties expressed in pathological tissues and fluids.

Additionally, the Johns Hopkins Medicine Multiple Sclerosis Center has acquired a Ciphergen proteomics machine (SELDI mass spectroscopy) that is capable of screening large numbers of clinical serum and CSF MS samples to screen for patterns of aberrant protein expression. This project has already been initiated and thus will be operative during years 1-5 of the project.

«« back to Research Overview


Related Links

Attacking Two Brain Disorders on Multiple Fronts
Uncover how Hopkins researchers are finding new treatments and diagnostic tools to treat multiple sclerosis and transverse myelitis.

Looking Forward

Read the latest issue of our newsletter

Looking Forward Fall 2014 cover

Previous Issues

Out-of-State and International Patients - Find Out More


© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.